Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 263 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: morphine Placebo Clear all
Completed Phase 4 Interventional

Opiate-Induced Tolerance & Hyperalgesia in Pain Patients

NCT00246532
View directory record Official record
Conditions
Chronic Low Back Pain, Opioid-induced Hyperalgesia
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery

NCT03241485
View directory record Official record
Conditions
Pain
Interventions
Intrathecal morphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 4, 2026, 7:49 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

NCT04614610
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions
Lidocaine Iv, Placebo
Drug
Lead sponsor
Community Medical Center, Toms River, NJ
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 4, 2026, 7:49 AM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

NCT00390039
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intranasal morphine, Placebo, IV morphine
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
7
States / cities
Phoenix, Arizona • Bakersfield, California • State College, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2008 · Synced Sep 4, 2026, 7:49 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination

NCT04218409
View directory record Official record
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, Oxytocin nasal spray, Placebo Oxycodone, Placebo oxytocin, OxyCODONE 2.5 mg Oral Tablet
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine's Dose Response Curve

NCT00460239
View directory record Official record
Conditions
Opioid-related Disorders
Interventions
Buprenorphine, Morphine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Ketamine For Acute Treatment of Pain in Emergency Department

NCT02306759
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
The Brooklyn Hospital Center
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

NCT04310579
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial

NCT03080493
View directory record Official record
Conditions
Abortion, Induced, Cervical Preparation, Pain
Interventions
Gabapentin 600mg, Placebo oral capsule, acetaminophen/codeine and ibuprofen
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

NCT04121221
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
GA Depot, Placebo
Drug · Other
Lead sponsor
Mapi Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional

Pramipexole and Morphine for Renal Colic

NCT04160520
View directory record Official record
Conditions
Renal Colic
Interventions
Pramipexole, Morphine, Placebo oral tablet
Drug
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 66 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 4, 2026, 7:49 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

NCT00941304
View directory record Official record
Conditions
Dental Pain
Interventions
Oxycodone, Buprenorphine, Placebo Film, Placebo Capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 45 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Austin, Texas • San Marcos, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 4, 2026, 7:49 AM EDT
Active, not recruiting Phase 3 Interventional

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

NCT04188418
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Fentanyl Citrate Buccal Tablet, Morphine, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Placebo, EyeLink 1000 Plus, Oculo-Cognitive Addition test (OCAT), VT3mini - Eye Tracking Technology for OEMs
Drug · Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 59 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

NCT01642030
View directory record Official record
Conditions
Opioid Dependence, Pain, Addiction
Interventions
Placebo, Hydromorphone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Discriminative Effects of Tramadol in Humans

NCT00499746
View directory record Official record
Conditions
Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
Interventions
tramadol, placebo, Hydromorphone, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Months to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 1 Interventional Results available

Opioid and Cannabinoid Interactions

NCT03705559
View directory record Official record
Conditions
Marijuana Usage, Opioid Use
Interventions
Vaporized Marijuana, Opioid Agonist, Placebo
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 4, 2026, 7:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

NCT03880487
View directory record Official record
Conditions
Analgesia
Interventions
KP-1199, Placebo oral capsule, Oxycodone oral capsule
Drug
Lead sponsor
Kalyra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 4, 2026, 7:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

NCT02509312
View directory record Official record
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 4, 2026, 7:49 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty

NCT03774836
View directory record Official record
Conditions
Pain Management
Interventions
Tramadol, Morphine, Placebo
Drug · Other
Lead sponsor
Avenue Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Pasadena, California • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 4, 2026, 7:49 AM EDT